Phacilitate cell and gene therapy automation special interest group report 2019

Automation Special Interest Group: Report 2019

The 2019 Automation SIG identified some of the biggest opportunities to improve manufacturing efficiency and accuracy. This report comprises 14 chapters that summarise the discussions and implementable strategies from the SIG meeting
After a string of approved advanced therapies over the past few years, we are moving well beyond a proof of concept and we’re now looking at a sea change in the standard of healthcare worldwide.
It’s no secret that advanced therapies that are both on the market and in development are blighted by spiralling COGs and manufacturing inefficiencies and technical challenges.
Automation is the most efficient solution for reducing cost and process complexity and increasing productivity when it comes to advanced therapies. However, the decision on how, when, and what to automate is far from easy. A common yet flawed approach is waiting to get a therapy approved before considering automation, but with the forementioned approvals, that ‘later’ has suddenly become ‘now’.
This is really why the Automation SIG was created; to provide an annual gathering of industry leaders, tool developers and engineers with a collaborative environment where experience and knowledge can be easily shared, and solutions worked on throughout the year.
This report is written by the rapporteurs that led each themed working group and provides a summary of the findings and outcomes of the live discussions and polls. The report’s 14 chapters are divided into four parts for easy navigation:
  1. Making business sense of automation
  2. Strategic data, analytics and technology management
  3. Innovation in process technology
  4. Speeding up commercialisation
Phacilitate Automation SIG report 2019
Phacilitate Automation SIG report 2019